Compare Medpace Holdings Inc (MEDP) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Ross Stores, Inc. — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Ross Stores, Inc. trades at $222.41 (market cap $71.94B). The key difference: Ross Stores, Inc. is far larger — about 4.3× Medpace Holdings Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Ross Stores, Inc. for 48 Days on average.
| MEDP | ROST | |
|---|---|---|
Market Cap | $16.82B | $71.94B |
Volume | 223,093 | 2,002,519 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $255.23 |
52-Week Low | $393.42 | $147.71 |
Typical Hold Time | 14 Days | 48 Days |
Enterprise Value | $16.44B | $72.39B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Ross Stores (ROST) trades at $225.2, down 0.15% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.66 surpassing the $1.95 forecast. Revenue grew to $21.13B in 2025, and net income margin improved to 10.85%. Analyst consensus is bullish with a $274.14 price target, though technical indicators show resistance near $226.
The outlook for ROST is positive due to robust earnings performance, store expansion initiatives, and strong profitability metrics like a 42.63% ROE. Risks include competitive pressures and rising costs, but institutional buying and a high analyst buy rating (63.83%) support upside potential. The stock presents a compelling opportunity for growth investors seeking value in the discount retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
